JP2009518306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518306A5 JP2009518306A5 JP2008543528A JP2008543528A JP2009518306A5 JP 2009518306 A5 JP2009518306 A5 JP 2009518306A5 JP 2008543528 A JP2008543528 A JP 2008543528A JP 2008543528 A JP2008543528 A JP 2008543528A JP 2009518306 A5 JP2009518306 A5 JP 2009518306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- antigen
- suspension
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 54
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 239000002105 nanoparticle Substances 0.000 claims 18
- 239000000725 suspension Substances 0.000 claims 13
- 230000028993 immune response Effects 0.000 claims 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 5
- 239000002577 cryoprotective agent Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 244000052769 pathogen Species 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 238000004108 freeze drying Methods 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical group BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 230000029662 T-helper 1 type immune response Effects 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000001571 immunoadjuvant effect Effects 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229940065514 poly(lactide) Drugs 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920002721 polycyanoacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74186005P | 2005-12-02 | 2005-12-02 | |
| US60/741,860 | 2005-12-02 | ||
| US77526506P | 2006-02-21 | 2006-02-21 | |
| US60/775,265 | 2006-02-21 | ||
| PCT/US2006/046212 WO2008051245A2 (en) | 2005-12-02 | 2006-12-01 | Nanoparticles for use in immunogenic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168462A Division JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009518306A JP2009518306A (ja) | 2009-05-07 |
| JP2009518306A5 true JP2009518306A5 (https=) | 2011-01-06 |
| JP5806444B2 JP5806444B2 (ja) | 2015-11-10 |
Family
ID=39204901
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543528A Expired - Fee Related JP5806444B2 (ja) | 2005-12-02 | 2006-12-01 | 免疫原性組成物で使用するためのナノ粒子 |
| JP2013168462A Pending JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168462A Pending JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9393215B2 (https=) |
| EP (1) | EP1954252B1 (https=) |
| JP (2) | JP5806444B2 (https=) |
| CA (1) | CA2631714C (https=) |
| ES (1) | ES2564241T3 (https=) |
| WO (1) | WO2008051245A2 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| WO2006081576A2 (en) | 2005-01-28 | 2006-08-03 | Galenbio, Inc. | Immunologically active compositions |
| WO2008051245A2 (en) | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| US20090074670A1 (en) * | 2007-09-07 | 2009-03-19 | Yousef Haik | Hyperthermia Therapeutic Agent Delivery System |
| CA2722765C (en) | 2008-04-28 | 2016-10-04 | Novartis Ag | Nanoparticles for use in pharmaceutical compositions |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| MX2010014026A (es) * | 2008-06-27 | 2011-02-15 | Pfizer | Composiciones adyuvantes novedosas. |
| CA2733147A1 (en) * | 2008-08-06 | 2010-02-11 | Novartis Ag | Microparticles for use in immunogenic compositions |
| US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| CA2762653A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| BR112012025047A2 (pt) | 2010-03-31 | 2016-06-21 | Stabilitech Ltd | formulações líquidas estabilizadas |
| EP2552410B1 (en) | 2010-03-31 | 2018-10-24 | Stabilitech Biopharma Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| HUE026885T2 (en) | 2010-03-31 | 2016-08-29 | Stabilitech Ltd | Stabilize virus fragments |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| PL2594140T3 (pl) * | 2010-07-16 | 2019-09-30 | Universidad De Navarra | Nanocząstki do kapsułkowania związków, ich wytwarzanie i zastosowanie |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US20120058153A1 (en) * | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin |
| MX350927B (es) | 2010-08-26 | 2017-09-26 | Toray Ind Inc Star | Composicion inmunogenica. |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| AR084158A1 (es) * | 2010-12-10 | 2013-04-24 | Merck Sharp & Dohme | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas |
| EP2661253B1 (en) * | 2011-01-04 | 2017-04-19 | Archivel Farma, SL | Liposome formulation suitable for treating or preventing tuberculosis |
| US10286056B2 (en) * | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| JP6099573B2 (ja) * | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法 |
| CA2830948A1 (en) * | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| PL2696848T3 (pl) | 2011-04-15 | 2020-12-28 | Janssen Pharmaceutica N.V. | Liofilizowane nanozawiesiny leków |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| ES2670493T3 (es) | 2012-01-12 | 2018-05-30 | Archivel Farma, S.L. | Vacuna de MTB-C contra respuestas alérgicas |
| EP3586829A1 (en) | 2012-01-20 | 2020-01-01 | South Dakota State University | Inulin and inulin acetate formulations |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| US9546361B2 (en) | 2012-10-12 | 2017-01-17 | Lehigh University | Thermally stable enzymes, compositions thereof and methods of using same |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| FI20126281L (fi) * | 2012-12-10 | 2014-06-11 | Filana Ltd Oy | Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| SG10201803780UA (en) | 2013-11-04 | 2018-06-28 | Uti Lp | Methods and compositions for sustained immunotherapy |
| WO2015116775A1 (en) * | 2014-01-30 | 2015-08-06 | Trudeau Institute | Nanoparticles for immune stimulation |
| MA39734B1 (fr) | 2014-03-14 | 2019-07-31 | Pfizer | Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| ES3055030T3 (en) | 2015-05-06 | 2026-02-09 | Uti Lp | Nanoparticle compositions for sustained therapy |
| EP4494650A3 (en) | 2015-09-03 | 2025-03-26 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| JP2019511255A (ja) | 2016-01-11 | 2019-04-25 | バーンダリ，インク． | マイクロニードル組成物およびそれを使用する方法 |
| ES2847249T3 (es) * | 2016-03-23 | 2021-08-02 | Academia Sinica | Nanopartículas poliméricas de envoltura delgada y usos de las mismas |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| WO2019023196A1 (en) | 2017-07-24 | 2019-01-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE |
| EP3716949A4 (en) | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | Methods of treating autoimmune disease |
| EP3768308A4 (en) | 2018-03-19 | 2022-01-26 | Novavax, Inc. | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES |
| MX2020011166A (es) * | 2018-04-25 | 2022-10-19 | Ethris Gmbh | Agentes crioprotectores para formulaciones en forma de particulas. |
| US10874737B2 (en) | 2018-06-01 | 2020-12-29 | Iowa State University Research Foundation, Inc. | Influenza nanovaccine |
| WO2020222541A1 (ko) * | 2019-04-30 | 2020-11-05 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| US12233177B2 (en) | 2019-09-16 | 2025-02-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
| EP4404919A4 (en) * | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| WO2023183082A1 (en) | 2022-03-24 | 2023-09-28 | The Regents Of The University Of California | Silyl lipids suitable for enhanced delivery of anti-viral therapeutics |
| CA3246538A1 (en) | 2022-03-30 | 2023-10-05 | Evonik Operations Gmbh | Formulations composed of cationic lipids and poly(lactic-co-glycolic acid) for the administration of polynucleotides into cells |
| JPWO2024180926A1 (https=) * | 2023-02-28 | 2024-09-06 | ||
| WO2024215719A2 (en) * | 2023-04-10 | 2024-10-17 | Academia Sinica | Composition, vaccine and method for treating influenza a |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| FR2634397B2 (fr) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
| FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| FR2742357B1 (fr) * | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| ATE230923T1 (de) * | 1997-02-07 | 2003-02-15 | Elan Drug Delivery Ltd | Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen |
| CN100471522C (zh) * | 1998-03-13 | 2009-03-25 | 惠氏 | 聚核苷酸组合物及其制备方法与用途 |
| AU763975B2 (en) | 1998-07-29 | 2003-08-07 | Novartis Vaccines And Diagnostics, Inc. | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| MXPA03002640A (es) | 2000-09-28 | 2003-06-19 | Chiron Corp | Microparticulas para la distribucion de acidos nucleicos heterologos. |
| ATE350015T1 (de) * | 2000-09-28 | 2007-01-15 | Novartis Vaccines & Diagnostic | Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung |
| DE10214031A1 (de) * | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
| SI2371392T1 (sl) | 2002-05-02 | 2015-10-30 | Wyeth Holdings Llc | Konjugati derivat-nosilec kaliheamicina |
| AU2003256912A1 (en) * | 2002-08-16 | 2004-03-03 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| US20040105778A1 (en) | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| AU2003299994A1 (en) * | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| US20050244505A1 (en) * | 2003-12-11 | 2005-11-03 | Higbee Russell G | Immunotherapy compositions, method of making and method of use thereof |
| WO2008051245A2 (en) | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
-
2006
- 2006-12-01 WO PCT/US2006/046212 patent/WO2008051245A2/en not_active Ceased
- 2006-12-01 EP EP06851781.2A patent/EP1954252B1/en active Active
- 2006-12-01 JP JP2008543528A patent/JP5806444B2/ja not_active Expired - Fee Related
- 2006-12-01 US US12/095,655 patent/US9393215B2/en active Active
- 2006-12-01 ES ES06851781.2T patent/ES2564241T3/es active Active
- 2006-12-01 CA CA2631714A patent/CA2631714C/en not_active Expired - Fee Related
-
2013
- 2013-08-14 JP JP2013168462A patent/JP2013227354A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518306A5 (https=) | ||
| Lebre et al. | Modulation of immune responses by particulate materials | |
| Chang et al. | Recent advances in hyperthermia therapy‐based synergistic immunotherapy | |
| JP2006526649A5 (https=) | ||
| Zhou et al. | Biomimetic nanotechnology toward personalized vaccines | |
| Sun et al. | Nanomaterial-based vaccine adjuvants | |
| CA2528007A1 (en) | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen | |
| KR20230093248A (ko) | 전 세포 성분이 로딩된 표적 수송 시스템 및 이의 용도 | |
| CN114225021B (zh) | 基于一种或多种癌细胞和/或肿瘤组织全细胞组分或其混合物的预防或治疗癌症的疫苗系统 | |
| Hajizade | Nanoparticles in vaccine development | |
| Goyal et al. | Aquasomes—a nanoparticulate approach for the delivery of antigen | |
| Kumari et al. | Biomaterials-based formulations and surfaces to combat viral infectious diseases | |
| JP2007534728A (ja) | メチルビニルエーテル−無水マレイン酸コポリマーを基材とするナノ粒子を含んでなる免疫応答刺激組成物 | |
| JP2009527572A5 (https=) | ||
| Schully et al. | Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis | |
| JP2011506334A5 (https=) | ||
| TW200936145A (en) | Functional nanoparticle-based antibiotics and preparation method thereof | |
| WO2023040121A1 (zh) | 基于多种癌细胞和/或肿瘤组织全细胞组分的预防或治疗癌症的疫苗系统及其制备与应用 | |
| KR20200038339A (ko) | 다가 vlp 접합체 | |
| Tafaghodi et al. | Polymer-based nanoparticles as delivery systems for treatment and vaccination of tuberculosis | |
| Yoon et al. | Enhanced efficacy of immunization with a foot-and-mouth disease multi-epitope subunit vaccine using mannan-decorated inulin microparticles | |
| Nordin et al. | Natural polymeric composites derived from animals, plants, and microbes for vaccine delivery and adjuvant applications: A review | |
| WO2023040127A1 (zh) | 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用 | |
| JP2008507590A (ja) | 免疫活性剤を経皮送達するための方法及び配合物 | |
| Vuppu et al. | Nanovaccines for veterinary applications |